{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T19:10:27Z","timestamp":1684005027479},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,21]],"date-time":"2013-07-21T00:00:00Z","timestamp":1374364800000},"content-version":"vor","delay-in-days":2393,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.curtheres.2007.03.002","type":"journal-article","created":{"date-parts":[[2007,8,9]],"date-time":"2007-08-09T11:38:50Z","timestamp":1186659530000},"page":"1-22","source":"Crossref","is-referenced-by-count":0,"title":["Tolerability of intravenous pamidronate for the treatment of osteoporosis and other metabolic osteopathies: A retrospective analysis"],"prefix":"10.1016","volume":"68","author":[{"given":"Marcelo","family":"Sarli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Spivacow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Pedroarias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio J.A.","family":"Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 R.","family":"Zanchetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2007.03.002_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2265.1991.tb00294.x","article-title":"Intravenous aminobisphosphonate in Paget's disease: Clinical, biochemical, histomorphometric and radiological responses","volume":"34","author":"Fenton","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.curtheres.2007.03.002_bib2","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial","volume":"14","author":"Conte","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.curtheres.2007.03.002_bib3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/jbmr.5650100808","article-title":"Intravenous pamidronate in patients with tumor-induced osteolysis: A biochemical dose-response study","volume":"10","author":"Body","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.curtheres.2007.03.002_bib4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(94)90069-8","article-title":"Long-term effects of intravenous pamidronate in fibrous dysplasia of bone","volume":"343","author":"Liens","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.curtheres.2007.03.002_bib5","first-page":"289","article-title":"Treatment of multiple myeloma with intravenous pamidronate. Pain prevention and suppression of hypercalcemia risk [in Spanish]","volume":"64","author":"D\u00edaz","year":"2004","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.curtheres.2007.03.002_bib6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/BF00194339","article-title":"Serum kinetics, bioavailability and bone scanning of 99mTc-labelled sodium olpadronate in patients with different rates of bone turnover","volume":"48","author":"Degrossi","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2007.03.002_bib7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s002239900353","article-title":"An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates","volume":"61","author":"Thiebaud","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.curtheres.2007.03.002_bib8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/BF00298594","article-title":"Ototoxicity associated with intravenous bisphosphonate administration","volume":"56","author":"Reid","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.curtheres.2007.03.002_bib9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1742-1241.1995.tb09976.x","article-title":"Paget's disease: Ocular complications of disodium pamidronate treatment","volume":"49","author":"O'Donnell","year":"1995","journal-title":"Br J Clin Pract"},{"key":"10.1016\/j.curtheres.2007.03.002_bib10","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/ajkd.2002.32797","article-title":"Nephrotic syndrome after treatment with pamidronate","volume":"39","author":"Markowitz","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.curtheres.2007.03.002_bib11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0002-9394(14)72902-2","article-title":"Pamidronate disodium and possible ocular adverse drug reactions","volume":"118","author":"Macarol","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.curtheres.2007.03.002_bib12","first-page":"446","article-title":"Treatment of post menopausal osteoporosis with intravenous pamidronate in patients with esophagogastric pathology [in Spanish]","volume":"58","author":"Sarli","year":"1998","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.curtheres.2007.03.002_bib13","first-page":"14","article-title":"Postmenopausal osteoporosis treatment with intravenous pamidronate [in Spanish]","volume":"41","author":"Spivacow","year":"2004","journal-title":"Rev Arg Endocrinol Metab"},{"key":"10.1016\/j.curtheres.2007.03.002_bib14","first-page":"1504","article-title":"A randomized controlled trial of APD (disodium pamidronate) given intravenously with and without sodium fluoride in involutional osteoporosis","volume":"Vol. III","author":"Devogelaer","year":"1990"},{"key":"10.1016\/j.curtheres.2007.03.002_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF01623227","article-title":"Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause","volume":"4","author":"Thiebaud","year":"1994","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.curtheres.2007.03.002_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0378-5122(96)01118-8","article-title":"Cyclical pamidronate infusions in postmenopausal osteoporosis","volume":"25","author":"Peretz","year":"1996","journal-title":"Maturitas"},{"key":"10.1016\/j.curtheres.2007.03.002_bib17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002239900334","article-title":"Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial","volume":"61","author":"Boutsen","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.curtheres.2007.03.002_bib18","first-page":"664","article-title":"Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans","volume":"77","author":"Rosen","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.curtheres.2007.03.002_bib19","first-page":"254","article-title":"Uso de pamidronato dis\u00f3dico (APD) por v\u00eda intravenosa en mujeres posmenop\u00e1usicas","volume":"33","author":"Pozzo","year":"1996","journal-title":"Rev Argent Endocrinol Metab"},{"key":"10.1016\/j.curtheres.2007.03.002_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0011-393X(96)80006-3","article-title":"Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseases","volume":"57","author":"Spivacow","year":"1996","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.curtheres.2007.03.002_bib21","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/0169-6009(92)92281-T","article-title":"Side effects verified during treatment of 228 cases of involutional osteoporosis with pamidronate","author":"Fromm","year":"1992","journal-title":"Bone Miner"},{"key":"10.1016\/j.curtheres.2007.03.002_bib22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0011-393X(99)80007-1","article-title":"Effects of treatment with bisphosphonates on gastrointestinal and esophageal mucosa in patients with osteoporosis: Pamidronate versus alendronate","volume":"60","author":"Herrera","year":"1999","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.curtheres.2007.03.002_bib23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.amjmed.2003.12.019","article-title":"Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy","volume":"116","author":"Kim","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.curtheres.2007.03.002_bib24","series-title":"Clinical Pharmacokinetics and Pharmacodynamics of Bisphosphonates in Metabolic Bone Diseases","year":"2003"},{"key":"10.1016\/j.curtheres.2007.03.002_bib26","series-title":"Biological Variation: From Principles to Practice","year":"2001"},{"key":"10.1016\/j.curtheres.2007.03.002_bib27","first-page":"845","article-title":"Intra- and inter-individual biological variability data bank","volume":"35","author":"Sebastian-Gambaro","year":"1997","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"10.1016\/j.curtheres.2007.03.002_bib28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/00365519950185229","article-title":"Current databases on biologic variation: Pros, cons, and progress","volume":"59","author":"Ricos","year":"1999","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.curtheres.2007.03.002_bib29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1359\/jbmr.2002.17.6.1057","article-title":"Daily oral pamidronate in women and men with osteoporosis: A 3-year randomized placebo-controlled clinical trial with a 2-year open extension","volume":"17","author":"Brumsen","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2007.03.002_bib30","first-page":"37","article-title":"Extended use, up to 6 years, of an oral amino-bisphosphonate in patients with established osteoporosis [in Spanish]","volume":"57","author":"Zanchetta","year":"1997","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.curtheres.2007.03.002_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1445-5994.1996.tb01932.x","article-title":"Iritis following intravenous pamidronate","volume":"26","author":"Stewart","year":"1996","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.curtheres.2007.03.002_bib32","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1600-051X.2005.00842.x","article-title":"Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment","volume":"32","author":"Ficarra","year":"2005","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.curtheres.2007.03.002_bib33","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.14219\/jada.archive.2005.0109","article-title":"Bisphosphonate-associated osteonecrosis of the jaws: A review of current knowledge","volume":"136","author":"Markiewicz","year":"2005","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.curtheres.2007.03.002_bib34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected]review: Bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med. 2006;145:235]","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X07000173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X07000173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T18:43:43Z","timestamp":1684003423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X07000173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0011393X07000173"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2007.03.002","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}